Pascal Touchon, Atara CEO
ASH: With PhIII data in hand, Atara eyes a submission to treat a small but desperate group of transplant patients
After more than two decades in the clinic, Atara Biotherapeutics’ T cell therapy tabelecleucel is finally headed to the FDA — but not without a pivotal readout at this year’s ASH conference.
About half of patients responded to tab-cel, Atara’s candidate for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), a rare complication that can occur after solid organ or hematopoietic stem cell transplant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
